Clinical Trials Packaging Programs Therapy 
Cannabis Law Report
OCTOBER 2, 2021
MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. Holiday Pay.
Cannabis Law Report
NOVEMBER 19, 2021
MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Holiday Pay.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JANUARY 31, 2022
Numinus Bioscience said that it is prepared to supply psilocybin in whole mushroom form, through three packaged doses equivalent to 10, 15, and 25mg of psilocybin. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. (TSX-V:NUMI,
Cannabis Law Report
NOVEMBER 19, 2021
MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Position Requirements.
Puff Puff Post
NOVEMBER 5, 2019
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.
Cannabis Law Report
JANUARY 9, 2019
Then I saw someone with Stage 4 breast cancer end up in remission from cannabis-based therapy, someone else with skin cancer; kid after kid with seizures all being treated. Tindall also hope to commence the clinical trials with Vanuatu for diabetes treatment. It also gives us a fast-track program.
Cannabis Law Report
AUGUST 25, 2022
In addition to the clinical research program to make MDMA into an FDA-approved medicine, MAPS was founded to create sensible and compassionate alternatives to the War on Drugs. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD.
Expert insights. Personalized for you.
52 
Let's personalize your content